
Hatteras Venture Partners
Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
RapidPulse | Jul 2026Participated | $48 MSeries B | |
410 Medical | Jul 2026Participated | $12 MOther Equity | |
Ladder Health | Jun 2026Participated | $7 MSeed | |
Create Medicines | May 2026Led | $122 MSeries B | |
Incyclix Bio | Apr 2026Led | $5 MSeries B | |
Pharaoh Neuro | Feb 2026Participated | $20 MSeries A | |
Boomerang Medical | Sep 2025Led | $20 MSeries B | |
Sensorium Therapeutics | Aug 2025Participated | $25 MSeries A | |
GeneCentric Therapeutics | Jun 2025Led | $8 MSeries C | |
Atsena Therapeutics | Apr 2025Participated | $150 MSeries C | |
BEKHealth | Feb 2025Led | $4 MOther Equity | |
Axonis Therapeutics | Oct 2024Participated | $115 MSeries A | |
RapidPulse | Jul 2026Participated | $48 MSeries B | |
410 Medical | Jul 2026Participated | $12 MOther Equity | |
Ladder Health | Jun 2026Participated | $7 MSeed | |
Create Medicines | May 2026Led | $122 MSeries B | |
Incyclix Bio | Apr 2026Led | $5 MSeries B | |
Pharaoh Neuro | Feb 2026Participated | $20 MSeries A | |
Boomerang Medical | Sep 2025Led | $20 MSeries B | |
Sensorium Therapeutics | Aug 2025Participated | $25 MSeries A | |
GeneCentric Therapeutics | Jun 2025Led | $8 MSeries C | |
Atsena Therapeutics | Apr 2025Participated | $150 MSeries C | |
BEKHealth | Feb 2025Led | $4 MOther Equity | |
Axonis Therapeutics | Oct 2024Participated | $115 MSeries A |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 1 | 3 |
| Series A | 10 | 21 |
| Series B | 10 | 14 |
| Series C+ | 2 | 14 |
| Other Equity | 6 | 15 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jan '10 | 1 |
| Feb '10 | 1 |
| Mar '10 | 0 |
| Apr '10 | 0 |
| May '10 | 0 |
| Jun '10 | 0 |
| Jul '10 | 0 |
| Aug '10 | 0 |
| Sep '10 | 0 |
| Oct '10 | 0 |
| Nov '10 | 0 |
| Dec '10 | 1 |
| Jan '11 | 0 |
| Feb '11 | 0 |
| Mar '11 | 0 |
| Apr '11 | 0 |
| May '11 | 0 |
| Jun '11 | 0 |
| Jul '11 | 0 |
| Aug '11 | 0 |
| Sep '11 | 1 |
| Oct '11 | 0 |
| Nov '11 | 0 |
| Dec '11 | 0 |
| Jan '12 | 1 |
| Feb '12 | 1 |
| Mar '12 | 0 |
| Apr '12 | 0 |
| May '12 | 1 |
| Jun '12 | 1 |
| Jul '12 | 1 |
| Aug '12 | 0 |
| Sep '12 | 0 |
| Oct '12 | 0 |
| Nov '12 | 0 |
| Dec '12 | 0 |
| Jan '13 | 1 |
| Feb '13 | 0 |
| Mar '13 | 0 |
| Apr '13 | 0 |
| May '13 | 0 |
| Jun '13 | 0 |
| Jul '13 | 0 |
| Aug '13 | 0 |
| Sep '13 | 0 |
| Oct '13 | 2 |
| Nov '13 | 0 |
| Dec '13 | 1 |
| Jan '14 | 0 |
| Feb '14 | 0 |
| Mar '14 | 0 |
| Apr '14 | 0 |
| May '14 | 1 |
| Jun '14 | 0 |
| Jul '14 | 0 |
| Aug '14 | 1 |
| Sep '14 | 1 |
| Oct '14 | 1 |
| Nov '14 | 0 |
| Dec '14 | 0 |
| Jan '15 | 1 |
| Feb '15 | 3 |
| Mar '15 | 2 |
| Apr '15 | 2 |
| May '15 | 2 |
| Jun '15 | 1 |
| Jul '15 | 0 |
| Aug '15 | 0 |
| Sep '15 | 2 |
| Oct '15 | 1 |
| Nov '15 | 0 |
| Dec '15 | 1 |
| Jan '16 | 0 |
| Feb '16 | 0 |
| Mar '16 | 1 |
| Apr '16 | 0 |
| May '16 | 1 |
| Jun '16 | 0 |
| Jul '16 | 0 |
| Aug '16 | 0 |
| Sep '16 | 0 |
| Oct '16 | 0 |
| Nov '16 | 0 |
| Dec '16 | 0 |
| Jan '17 | 1 |
| Feb '17 | 0 |
| Mar '17 | 2 |
| Apr '17 | 0 |
| May '17 | 0 |
| Jun '17 | 1 |
| Jul '17 | 0 |
| Aug '17 | 0 |
| Sep '17 | 1 |
| Oct '17 | 1 |
| Nov '17 | 1 |
| Dec '17 | 1 |
| Jan '18 | 1 |
| Feb '18 | 0 |
| Mar '18 | 2 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 1 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 1 |
| Oct '18 | 1 |
| Nov '18 | 2 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 1 |
| Jun '19 | 0 |
| Jul '19 | 1 |
| Aug '19 | 1 |
| Sep '19 | 0 |
| Oct '19 | 1 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 1 |
| May '20 | 0 |
| Jun '20 | 1 |
| Jul '20 | 1 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 2 |
| Jan '21 | 1 |
| Feb '21 | 0 |
| Mar '21 | 3 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 2 |
| Jul '21 | 0 |
| Aug '21 | 1 |
| Sep '21 | 1 |
| Oct '21 | 1 |
| Nov '21 | 1 |
| Dec '21 | 1 |
| Jan '22 | 1 |
| Feb '22 | 1 |
| Mar '22 | 1 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 1 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 1 |
| Oct '22 | 0 |
| Nov '22 | 1 |
| Dec '22 | 1 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 2 |
| May '23 | 0 |
| Jun '23 | 2 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 2 |
| May '24 | 0 |
| Jun '24 | 1 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 1 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 1 |
| Mar '25 | 0 |
| Apr '25 | 1 |
| May '25 | 0 |
| Jun '25 | 1 |
| Jul '25 | 0 |
| Aug '25 | 1 |
| Sep '25 | 1 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 1 |
| Mar '26 | 0 |
| Apr '26 | 1 |
| May '26 | 1 |
| Jun '26 | 1 |
| Jul '26 | 2 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 92 |
| Enterprise Software | 6 |
| Data, Analytics & IT | 5 |
| Networks, Cloud & Communication | 4 |
| Consumer & Lifestyle | 3 |
| Developer Tools | 3 |
| Fintech | 2 |
| Manufacturing | 2 |
| Space & Frontier Tech | 1 |
| Hardware & Robotics | 1 |
| Marketing & Advertising | 1 |
| Media & Entertainment | 1 |
| AI & Machine Learning | 1 |
| Food & Agriculture | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 11 |
| $5M-$10M | 14 |
| $10M-$25M | 33 |
| $25M-$50M | 20 |
| $50M-$100M | 13 |
| $100M-$250M | 5 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 93 |
| Canada | 2 |
| Europe | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Alexandria Venture Investments | 13 |
| Mountain Group Partners | 12 |
| New Enterprise Associates | 11 |
| Fletcher Spaght Ventures | 8 |
| Johnson & Johnson Innovation | 8 |
| Labcorp | 6 |
| Atlas Venture | 5 |
| Excelerate Health Ventures | 5 |
| RA Capital Management | 5 |
| Sanofi Ventures | 5 |
| Syno Capital | 5 |
| Arboretum Ventures | 4 |
| AstraZeneca | 4 |
| Broadview Ventures | 4 |
| Cormorant Asset Management | 4 |
| Lilly Ventures | 4 |
| Lumira Ventures | 4 |
| MedImmune Ventures | 4 |
| Northpond Ventures | 4 |
| Osage University Partners | 4 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 29 | 30% |
| Participating | 67 | 70% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 14 | 48% |
| Co-led | 15 | 52% |
Team
Principal
General Partner
General Partner and Co-Founder
Venture Partner
Venture Partner
Venture Partner
General Partner
General Partner
Venture Partner